Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition

Nature Communications

Volumn 5, Issue , 2014, Pages

  Gormally, Michael V ^a,b,c   Dexheimer, Thomas S ^c   Marsico, Giovanni ^b   Sanders, Deborah A ^b   Lowe, Christopher ^a   Matak Vinkoviä, Dijana ^a   Michael, Sam ^c   Jadhav, Ajit ^c   Rai, Ganesha ^c   Maloney, David J ^c   Simeonov, Anton ^c   Balasubramanian, Shankar ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCNB1 PROTEIN; CDC25B PROTEIN; DOUBLE STRANDED DNA; FDI 6 PROTEIN; PROTEIN; PROTEIN INHIBITOR; SMALL INTERFERING RNA; THIAZOLE ORANGE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; CHROMATIN; FDI-6 COMPOUND; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; PYRIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

CANCER; DNA; GENE EXPRESSION; GENOME;

ARTICLE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS; CONSENSUS SEQUENCE; DISSOCIATION CONSTANT; DNA BINDING; DNA BINDING DOMAIN; DNA PROBE; DOWN REGULATION; FLUORESCENCE POLARIZATION; GEL MOBILITY SHIFT ASSAY; GENE ONTOLOGY; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; IC50; MCF 7 CELL LINE; MITOSIS; PHENOTYPE; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA SEQUENCE; TRANSCRIPTION INITIATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CHROMATIN; DRUG EFFECTS; GENETIC TRANSCRIPTION; METABOLISM;

BLOTTING, WESTERN; CHROMATIN; DOWN-REGULATION; FLUORESCENCE POLARIZATION; FORKHEAD TRANSCRIPTION FACTORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MCF-7 CELLS; PYRIDINES; THIOPHENES; TRANSCRIPTION, GENETIC;

EID: 84922947816     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6165     Document Type: Article

References (59)

1. Darnell, J. E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740-749 (2002).
2. Libermann, T. A. & Zerbini, L. F. Targeting transcription factors for cancer gene therapy. Curr. Gene Ther. 6, 17-33 (2006).
3. Laoukili, J., Stahl, M. & Medema, R. H. FoxM1: At the crossroads of ageing and cancer. Biochim. Biophys. Acta 1775, 92-102 (2007).
4. Vaquerizas, J. M., Kummerfeld, S. K., Teichmann, S. A. & Luscombe, N. M. A census of human transcription factors: function, expression and evolution. Nat. Rev. Genet. 10, 252-263 (2009).
5. Spitz, F. & Furlong, E. E. M. Transcription factors: from enhancer binding to developmental control. Nat. Rev. Genet. 13, 613-626 (2012).
6. Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
7. Szabova, L. et al. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 72, 4141-4153 (2012).
8. Zhou, J. et al. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS ONE 9, e96989 (2014).
9. Koehler, A. N., Shamji, A. F. & Schreiber, S. L. Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis. J. Am. Chem. Soc. 125, 8420-8421 (2003).
10. Berg, T. Inhibition of transcription factors with small organic molecules. Curr. Opin. Chem. Biol. 12, 464-471 (2008).
11. Koehler, A. N. A complex task? Direct modulation of transcription factors with small molecules. Curr. Opin. Chem. Biol. 14, 331-340 (2010).
12. Verdine, G. L. & Walensky, L. D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264-7270 (2007).
13. Dervan, P. B. Molecular recognition of DNA by small molecules. Bioorg. Med. Chem. 9, 2215-2235 (2001).
14. Walensky, L. D. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004).
15. Pop, M. S. et al. A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein. Mol. Cancer Ther. 13, 1492-1502 (2014).
16. Wonsey, D. R. & Follettie, M. T. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 65, 5181-5189 (2005).
17. Laoukili, J. et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell Biol. 7, 126-136 (2005).
18. McDonald, D. FoxM1 dances with mitosis. Nat. Cell Biol. 7, 108-110 (2005).
19. Teh, M. T. in Stem Cells and Cancer Stem Cells: Therapeutic Applications in Disease and Injury. Hayat, M. A.3 Springer Verlag, (2011).
20. Koo, C.-Y., Muir, K. W. & Lam, E. W. F. FOXM1: From cancer initiation to progression and treatment. Biochim. Biophys. Acta 1819, 28-37 2012.
21. Kwok, J. M.-M. et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res. 8, 24-34 (2010).
22. Carr, J. R., Park, H. J., Wang, Z., Kiefer, M. M. & Raychaudhuri, P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res. 70, 5054-5063 (2010).
23. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38, 1043-1048 (2006).
24. Priller, M. et al. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin. Cancer Res. 17, 6791-6801 (2011).
25. Teh, M.-T. Cells brainwashed by FOXM1: do they have potential as biomarkers of cancer? Biomarkers Med. 6, 499-501 (2012).
26. Littler, D. R. et al. Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence. Nucleic Acids Res. 38, 4527-4538 (2010).
27. Wang, Z. et al. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat. Rev. 36, 151-156 (2010).
28. Radhakrishnan, S. K. et al. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 66, 9731-9735 (2006).
29. Kwok, J. M.-M. et al. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol. Cancer Ther. 7, 2022-2032 (2008).
30. Hegde, N. S., Sanders, D. A., Rodriguez, R. & Balasubramanian, S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat. Chem. 3, 725-731 (2011).
31. Halasi, M. & Gartel, A. L. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 8, 1966-1967 (2009).
32. Zhang, L. et al. Antibiotic susceptibility of mammalian mitochondrial translation. FEBS Lett. 579, 6423-6427 (2005).
33. Gartel, A. L. Thiostrepton, proteasome inhibitors and FOXM1. Cell Cycle 10, 4341-4342 (2011).
34. Jameson, D. M. & Ross, J. A. Fluorescence polarization/anisotropy in diagnostics and imaging. Chem. Rev. 110, 2685-2708 (2010).
35. Simeonov, A. et al. Fluorescence spectroscopic profiling of compound libraries. J. Med. Chem. 51, 2363-2371 (2008).
36. Huang, R. et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci. Transl. Med. 3, 80ps16-80ps16 (2011).
37. Jadhav, A. et al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J. Med. Chem. 53, 37-51 (2010).
38. Parker, M. W., Lo Bello, M. & Federici, G. Crystallization of glutathione S-transferase from human placenta. J. Mol. Biol. 213, 221-222 (1990).
39. Reinhold, W. C. et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72, 3499-3511 (2012).
40. Bhat, U. G., Halasi, M. & Gartel, A. L. FoxM1 is a general target for proteasome inhibitors. PLoS ONE 4, e6593 (2009).
41. Nakamura, S. et al. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis 31, 2012-2021 (2010).
42. Leung, T. W. et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 507, 59-66 (2001).
43. Chen, X. et al. The forkhead transcription factor FOXM1 controls cell cycledependent gene expression through an atypical chromatin binding mechanism. Mol. Cell. Biol. 33, 227-236 (2012).
44. Sanders, D. A., Ross-Innes, C. S., Beraldi, D., Carroll, J. S. & Balasubramanian, S. Genome-wide mapping of FOXM1 binding reveals co binding with estrogen receptor alpha in breast cancer cells. Genome Biol. 14, R6 (2013).
45. Wierstra, I. & Alves, J. Despite its strong transactivation domain, transcription factor FOXM1c is kept almost inactive by two different inhibitory domains. in Biol. Chem. 387, 963-976 (2006).
46. Wierstra, I. & Alves, J. FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2. FEBS J. 273, 4645-4667 (2006).
47. Wierstra, I. & Alves, J. FOXM1, a typical proliferation-associated transcription factor. Biol. Chem. 388, 1257-1274 (2007).
48. Wiedemeyer, W. R. Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system. Front. Oncol. 4, 34 (2014).
49. Myatt, S. S. & Lam, E. W. F. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 7, 847-859 (2007).
50. Balli, D. et al. Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition. EMBO J. 32, 231-244 (2013).
51. Méndez, J. & Stillman, B. Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. Mol. Cell. Biol. 20, 8602-8612 (2000).
52. Kim, D. et al. TopHat2: accurate alignment of transcriptomes inthe presence of insertions, deletions and genefusions. Genome Biol. 14, R36 (2013).
53. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. EdgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2009).
54. Kumar, L. & E Futschik, M. Mfuzz: a software package for soft clustering of microarray data. Bioinformation 2, 5-7 (2007).
55. Consortium, E. P. The ENCODE (ENCyclopedia of DNA elements) project. Science 306, 636-640 (2004).
56. Feng, J., Liu, T., Qin, B., Zhang, Y. & Liu, X. S. Identifying ChIP-seq enrichment using MACS. Nat. Protoc. 7, 1728-1740 (2012).
57. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841-842 (2010).
58. Machanick, P. & Bailey, T. L. MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics 27, 1696-1697 (2011).
59. Abdel-Monem, M. I., Mohamed, O. S. & Bakhite, E. A. Fluorine-containing heterocycles: synthesis and some reactions of new 3-amino-2-functionalized-6-(2'-thienyl)-4-trifluoromethylthieno [2,3-b]pyridines. Pharmazie 56, 41-44 (2001).